Exelixis (EXEL) Receivables - Net (2012 - 2026)
Exelixis (EXEL) posted quarterly Receivables - Net of $328.9 million for Q2 2026, up 16.8% year-over-year from $281.6 million in Q2 2025, and up 14.65% quarter-over-quarter from $286.9 million in Q1 2026.
Analysis
Exelixis (EXEL) Receivables - Net (2012 - 2026) Analysis & Trends
Exelixis' Receivables - Net history runs 15 years deep, the most recent figure standing at $328.9 million for Q2 2026.
- In Q2 2026, Receivables - Net rose 16.8% year-over-year to $328.9 million; the TTM figure through Apr 2026 stood at $328.9 million (up 16.8% YoY), while the FY2026 annual figure was $286.9 million, up 8.09% from the prior year.
- Receivables - Net for Q2 2026 stood at $328.9 million, up from $286.9 million in the prior quarter.
- The five-year high for Receivables - Net was $396.6 million in Q2 2024, with the low at $190.6 million in Q2 2022.
- The 5-year median for Receivables - Net is $248.1 million (2023), against an average of $263.5 million.
- The sharpest annual moves came in 2024 and 2025: Receivables - Net soared 70.34% in 2024, then decreased 26.28% in 2025.
- Exelixis' Receivables - Net stood at $214.8 million in 2022, then grew by 10.53% to $237.4 million in 2023, then advanced by 13.6% to $269.7 million in 2024, then advanced by 14.84% to $309.7 million in 2025, then gained by 6.21% to $328.9 million in 2026.
- Business Quant data shows EXEL's Receivables - Net at $328.9 million in Q2 2026, $286.9 million in Q1 2026, and $309.7 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | 322.21 Mn |
| Apr 3, 2026 | 328.95 Mn |
| Jan 2, 2026 | 286.92 Mn |
| Oct 3, 2025 | 309.73 Mn |
| Jul 4, 2025 | 292.35 Mn |
| Apr 4, 2025 | 281.64 Mn |
| Jan 3, 2025 | 265.44 Mn |
| Sep 27, 2024 | 269.71 Mn |
| Jun 28, 2024 | 396.58 Mn |
| Mar 29, 2024 | 240.58 Mn |
| Dec 29, 2023 | 237.41 Mn |
| Sep 29, 2023 | 248.11 Mn |
| Jun 30, 2023 | 232.82 Mn |
| Mar 31, 2023 | 233.92 Mn |
| Dec 30, 2022 | 214.78 Mn |
| Sep 30, 2022 | 215.02 Mn |
| Jul 1, 2022 | 235.40 Mn |
| Apr 1, 2022 | 190.61 Mn |
| Dec 31, 2021 | 282.65 Mn |
| Oct 1, 2021 | 179.49 Mn |